NCT04262726 (REMOTION) is a NA clinical trial of REMOTION in Mental Disorders, sponsored by University of Bern.

Who is sponsoring NCT04262726?

NCT04262726 is sponsored by University of Bern.

What drugs are being tested in NCT04262726?

Interventions in NCT04262726: REMOTION, TAU.

What condition does NCT04262726 study?

NCT04262726 studies Mental Disorders.

Is NCT04262726 still recruiting?

NCT04262726 is currently completed. Last updated 10 January 2023.

Last reviewed 2023-01-10 · How we verify

NCT04262726: REMOTION

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

REMOTION: a Trial to Investigate the Feasibility and Potential Effectiveness of a Blended, Transdiagnostic Intervention for Symptom Reduction and Improvement of Emotion Regulation in an Outpatient Psychotherapeutic Setting

Completed NA Last updated 10 January 2023

What this trial tests

NA trial testing REMOTION in Mental Disorders in 70 participants. Completed in 27 November 2022.

Timeline

26 February 2020

Primary endpoint
27 November 2022

27 November 2022

Quick facts

Lead sponsor	University of Bern
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	70
Start date	26 February 2020
Primary completion	27 November 2022
Estimated completion	27 November 2022
Sites	1 location across Switzerland

Drugs / interventions tested

REMOTION
TAU — full drug profile →

Conditions studied

Mental Disorders — all drugs for Mental Disorders →

Sponsor

University of Bern

Who can join

Adults 18 to 70, any sex, with Mental Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Emotion regulation has been identified as an important transdiagnostic factor in the treatment of mental health disorders. This study aims to examine, for the first time, REMOTION, a novel blended therapy intervention aimed at reducing symptom severity and improving emotion regulation of patients in an outpatient psychotherapy setting. REMOTION is an internet based intervention that is administered as an add-on to psychotherapy. This study aims to investigate feasibility and also potential effectiveness of REMOTION in an outpatient setting. Participants will be randomly assigned to the study conditions. Outcomes are assessed at baseline, after six weeks and after twelve weeks.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Two sides of the same coin? Patient and therapist experiences with a transdiagnostic blended intervention focusing on emotion regulation.
Bielinski LL, Bur OT, Wälchli G, Suter JM, et al · · 2022 · cited 9× · PMID 36386404 · DOI 10.1016/j.invent.2022.100586
REMOTION Blended Transdiagnostic Intervention for Symptom Reduction and Improvement of Emotion Regulation in an Outpatient Psychotherapeutic Setting: Protocol for a Pilot Randomized Controlled Trial.
Bielinski LL, Krieger T, Moggi F, Trimpop L, et al · · 2020 · cited 8× · PMID 33180026 · DOI 10.2196/20936
Blending an internet-based emotion regulation intervention with face-to-face psychotherapy: Findings from a pilot randomized controlled trial.
Bielinski LL, Krieger T, Kley MA, Moggi F, et al · · 2023 · cited 3× · PMID 37575677 · DOI 10.1016/j.invent.2023.100650

Verify or expand the search:

Other trials of REMOTION

Trials testing the same drug.

NCT04990674 — Acute-REMOTION: REMOTION in Acute Psychiatric Care · NA · completed

Other recruiting trials for Mental Disorders

Currently open trials in the same condition.

NCT07466875 — Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients · NA · recruiting
NCT06810076 — Developing and Evaluating a Machine-Learning Opioid Overdose Prediction & Risk-Stratification Tool in Primary Care · NA · active not recruiting
NCT06387290 — Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits · Phase 3 · recruiting
NCT06673966 — Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in Schizophrenia · recruiting
NCT06930547 — Effectiveness of Smoking Cessation Education · NA · recruiting

Other University of Bern trials

Trials by the same sponsor.

NCT05940662 — Cost Effectiveness of Various Implant Placement Protocols in the Esthetic Zone · Phase 4 · suspended
NCT02919163 — Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 6 of 7) · NA · not yet recruiting
NCT02919189 — Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 5 of 7) · NA · not yet recruiting
NCT04817592 — Characterization of the Corneal Biomechanics of Patients Treated by Corneal Lenticule Extraction for Advanced Refractive · not yet recruiting
NCT06806150 — The INSPIRE Study: INvestigation of Swiss Physicians Inner-life, Resilience, and Emotions · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04262726 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Bern
Last refreshed: 10 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04262726.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing